Quick Answer
BioXcel Therapeutics, Inc. reported Net Income Loss of -$69.90 million for the year ending 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -17.3% in Net Income Loss from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$529.0 thousand | Q2 2017: -$565.0 thousand | Q3 2017: -$917.0 thousand | Q1 2018: -$4.28 million | Q2 2018: -$3.03 million | Q3 2018: -$4.89 million | Q1 2019: -$7.20 million | Q2 2019: -$8.47 million | Q3 2019: -$9.02 million | Q1 2020: -$14.91 million | Q2 2020: -$21.42 million | Q3 2020: -$24.75 million | Q1 2021: -$26.38 million | Q2 2021: -$27.62 million | Q3 2021: -$26.81 million | Q1 2022: -$31.47 million | Q2 2022: -$37.67 million | Q3 2022: -$41.81 million | Q1 2023: -$52.80 million | Q2 2023: -$53.52 million | Q3 2023: -$50.49 million | Q1 2024: -$26.79 million | Q2 2024: -$8.30 million | Q3 2024: -$13.65 million | Q1 2025: -$7.25 million | Q2 2025: -$19.19 million | Q3 2025: -$30.91 million.
- Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Net Income Loss has declined by 1,439.9%.
- Historical annual values: Fiscal year 2025: -$69.90 million | Fiscal year 2024: -$59.60 million | Fiscal year 2023: -$179.05 million | Fiscal year 2022: -$165.76 million | Fiscal year 2021: -$106.93 million | Fiscal year 2020: -$82.17 million | Fiscal year 2019: -$32.97 million | Fiscal year 2018: -$19.27 million | Fiscal year 2017: -$4.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: